The aim of the project is to assess brain network dynamics, self-referential information processing and prosociality and learning following the modulation of the serotonin-system by serotonergic-psychoactive compounds.
Topic Healthy Subjects
Country Switzerland
Visit trial
Status
Active, not recruiting
Results Published
Start date
01 December 2020
End date
01 October 2021
Phase
Phase I
Design
Blinded
Type
Interventional
Generation
First
Participants
30
Sex
Male
Age
20- 40
Therapy
No
Trial Details
The aim of the project is to assess brain network dynamics, self-referential information processing and prosociality and learning following the modulation of the serotonin-system by serotonergic-psychoactive compounds.Trial Number NCT04716335
Papers
Pharmacokinetics and Pharmacodynamics of an Innovative Psychedelic N,N-Dimethyltryptamine/Harmine Formulation in Healthy ParticipantsThis secondary analysis of an RCT (n=31) evaluates a novel pharmaceutical formulation of DMT and harmine in healthy male volunteers. The study finds that intranasal DMT and buccal harmine (pharmahuasca) produce consistent pharmacokinetic profiles and safe, well-tolerated effects resembling ayahuasca, with subjective experiences lasting 2–3 hours. This formulation is proposed as a safer, standardised alternative for potential therapeutic use in mental health disorders.